Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases

Rong Cai, … , Michael J. Welsh, Lei Liu

*J Clin Invest.* 2019;129(10):4539-4549. [https://doi.org/10.1172/JCI129987](https://doi.org/10.1172/JCI129987).

**Graphical abstract**

<table>
<thead>
<tr>
<th>Genetic defects</th>
<th>Terazosin → Glucose → Pgk1 → Pyruvate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental toxins</td>
<td>ATP ← Krebs cycle</td>
</tr>
<tr>
<td>Aging</td>
<td>Neurodegeneration → Parkinson’s disease</td>
</tr>
</tbody>
</table>

Find the latest version:

http://jci.me/129987/pdf
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases

Rong Cai,1,2 Yu Zhang,3 Jacob E. Simmering,4 Jordan L. Schultz,5 Yuhong Li,2 Irene Fernandez-Carasa,6 Antonella Consiglio,6,7 Angel Raya,8,9 Philip M. Polgreen,10 Nandakumar S. Narayanan,11 Yanpeng Yuan,1 Zhiguo Chen,1 Wenting Su,2 Yanping Han,1 Chunyue Zhao,12 Lifang Gao,2 Xuming Ji,12 Michael J. Welsh,13 and Lei Liu12

1Institute of Hypoxia Medicine, Xuanwu Hospital and Key Laboratory for Neurodegenerative Diseases of the Ministry of Education, and 2Center of Stroke, Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China. 3State Key Laboratory of Membrane Biology, School of Life Sciences, Peking University, Beijing, China. 4Department of Internal Medicine and 5Departments of Pharmaceutical Care and Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. 6Department of Pathology and Experimental Therapeutics, Bellvitge University Hospital-IDIBELL, Hospital del Llobregat and Institute of Biomedicine of the University of Barcelona (IBUB), Barcelona, Spain. 7Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 8Center of Regenerative Medicine in Barcelona (CMRB) and Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Hospital Duran i Reynals, Hospital del Llobregat, Barcelona, Spain. 9Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. 10Departments of Internal Medicine and Epidemiology and 11Department of Neurology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA. 12Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, Beihang University, Beijing, China. 13Howard Hughes Medical Institute, Departments of Internal Medicine, Neurology, and Molecular Physiology and Biophysics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.

Parkinson’s disease (PD) is a common neurodegenerative disease that lacks therapies to prevent progressive neurodegeneration. Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. Therefore, we asked whether enhancement of PGK1 activity would change the course of PD. In toxin-induced and genetic PD models in mice, rats, flies, and induced pluripotent stem cells, TZ increased brain ATP levels and slowed or prevented neuron loss. The drug increased dopamine levels and partially restored motor function. Because TZ is prescribed clinically, we also interrogated 2 distinct human databases. We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs. These findings suggest that enhancing PGK1 activity and increasing glycolysis may slow neurodegeneration in PD.

Introduction

Parkinson’s disease (PD) is the second most common neurodegenerative disease. It is estimated to affect approximately 6 million people worldwide, and its prevalence will increase further as populations age (1). Patients with PD suffer debilitating motor symptoms as well as nonmotor symptoms including dementia and neuropathic abnormalities (2, 3). Dopamine neurons in the substantia nigra pars compacta (SNc) and their projections into the striatum are especially susceptible to disruption in PD (4). Loss and impaired function of dopamine neurons cause the motor abnormalities that are a hallmark feature of PD. Although current treatments can sometimes relieve PD symptoms, no therapies prevent the neurodegeneration (5).

PD may have a number of different causes, and several pathogenic mechanisms have been proposed to contribute to the apoptotic death of neurons (6–10). In the majority of cases, the etiologies are unknown and probably complex. Aging, environmental toxins, and genetic mutations are all risk factors. In many cases, energy deficits and decreased ATP levels are observed in PD (11).

First, aging, the major risk factor for PD, impairs cerebral glucose metabolism, reduces mitochondrial biogenesis, and decreases ATP levels (12). Second, glycolysis and mitochondrial function are decreased in individuals with PD (13, 14). Third, mitochondrial toxins (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP], rotenone, paraquat) induce PD and PD-like phenotypes in cells and animals, including humans (15). Fourth, mutations associated with familial PD (e.g., PINK1, LRRK2, α-synuclein, parkin, DJ-1, CHCHD2) disrupt various aspects of energy metabolism (16). It is also hypothesized that SNc dopaminergic neurons may be particularly susceptible to PD neurodegeneration, because their highly branched, unmyelinated axonal arbor, their many neurotransmitter release sites, and their rhythmic firing engage a large metabolic burden (17). These considerations suggested that impaired bioenergetics and reduced ATP levels might contribute to the pathogenesis of PD, might modify the risk of developing PD in the face of PD risk factors, and/or might modify the course or severity of the disease.

We recently discovered that terazosin (TZ) binds and activates phosphoglycerate kinase 1 (PGK1) (18), the first ATP-generating enzyme in glycolysis (Figure 1A). TZ is an α1-adrenergic receptor antagonist that can relax smooth muscle and is prescribed to treat benign prostatic hyperplasia and, rarely, hypertension (19). However, biochemical and functional studies show that the effects of TZ on PGK1 are independent of α1-adrenergic

Parkinson’s disease (PD) may have a number of different causes, and several pathogenic mechanisms have been proposed to contribute to the apoptotic death of neurons (6–10). In the majority of cases, the etiologies are unknown and probably complex. Aging, environmental toxins, and genetic mutations are all risk factors. In many cases, energy deficits and decreased ATP levels are observed in PD (11).

First, aging, the major risk factor for PD, impairs cerebral glucose metabolism, reduces mitochondrial biogenesis, and decreases ATP levels (12). Second, glycolysis and mitochondrial function are decreased in individuals with PD (13, 14). Third, mitochondrial toxins (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP], rotenone, paraquat) induce PD and PD-like phenotypes in cells and animals, including humans (15). Fourth, mutations associated with familial PD (e.g., PINK1, LRRK2, α-synuclein, parkin, DJ-1, CHCHD2) disrupt various aspects of energy metabolism (16). It is also hypothesized that SNc dopaminergic neurons may be particularly susceptible to PD neurodegeneration, because their highly branched, unmyelinated axonal arbor, their many neurotransmitter release sites, and their rhythmic firing engage a large metabolic burden (17). These considerations suggested that impaired bioenergetics and reduced ATP levels might contribute to the pathogenesis of PD, might modify the risk of developing PD in the face of PD risk factors, and/or might modify the course or severity of the disease.

We recently discovered that terazosin (TZ) binds and activates phosphoglycerate kinase 1 (PGK1) (18), the first ATP-generating enzyme in glycolysis (Figure 1A). TZ is an α1-adrenergic receptor antagonist that can relax smooth muscle and is prescribed to treat benign prostatic hyperplasia and, rarely, hypertension (19). However, biochemical and functional studies show that the effects of TZ on PGK1 are independent of α1-adrenergic
antagonism (18). The crystal structure of TZ with PGK1 revealed that the 2, 4-diamino-6, 7-dimethoxyisoquinazoline motif of TZ binds PGK1 adjacent to the ADP/ATP binding site. In cultured cells, TZ enhanced PGK1 activity, thereby increasing ATP levels, and inhibited apoptosis (18).

The impaired energy production in PD, together with the ability of TZ to increase PGK1 activity, led us to hypothesize that increasing glycolysis in vivo might slow or prevent the apoptotic neurodegeneration of PD. To test this hypothesis, we used models of PD in flies, mice, rats, and human cells, and we interrogated patient databases to learn whether TZ altered the course of disease.

Results

**TZ increases brain ATP levels in vivo in mice.** To determine whether TZ would enhance glycolysis in vivo, we administered the drug to mice. TZ increased the levels of pyruvate, the product of glycolysis, in the SNc and striatum as well as in cortex (Figure 1, B and C, and Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/JCI129987DS1). Increased pyruvate enhances oxidative phosphorylation (20), and consistent with this finding, we observed that TZ increased citrate synthase activity, a marker of mitochondrial activity (Figure 1D and Supplemental Figure 1C). Correspondingly, we found that ATP levels increased (Figure 1E and Supplemental Figure 1D). Like previous in vitro data, the dose response was biphasic; our previous studies suggest that, at low but not high concentrations, TZ may enhance ATP release from PGK1 (18).

We also asked whether TZ would increase energy production in mice that received MPTP. MPTP causes PD in humans and is used to model PD in other animals (21, 22). Seven days after administration of MPTP to mice, pyruvate and ATP levels fell (Figure 1, F and G, and Supplemental Figure 2, A–C), and administration of TZ prevented the fall in pyruvate and ATP levels. Mitochondrial content (assessed by the ratio of mitochondrial DNA to nuclear DNA and by VDAC and PHB1 levels) also fell (Supplemental Figure 2, D–F). TZ partially prevented the decrease. As previously suggested (23), the increased pyruvate levels may have stimulated mitochondrial biogenesis. It would be difficult to measure ATP specifically in neurons, however, we observed similar changes in human neuroblastoma cells (Supplemental Figure 3, A–E). These data indicate that TZ activates glycolysis in vivo. Together with measurements of brain TZ levels (Supplemental Figure 3F), they also indicate that TZ readily crosses the blood-brain barrier.

Although PGK1 produces ATP, oxidative phosphorylation is probably important for increasing ATP on the basis of the following: (a) pyruvate, the product of glycolysis and major substrate for the citric acid cycle, increased (Figure 1, F and G, and Supplemental Figure 2, A–C), and administration of TZ prevented the fall in pyruvate and ATP levels. Mitochondrial content (assessed by the ratio of mitochondrial DNA to nuclear DNA and by VDAC and PHB1 levels) also fell (Supplemental Figure 2, D–F). TZ partially prevented the decrease. As previously suggested (23), the increased pyruvate levels may have stimulated mitochondrial biogenesis. It would be difficult to measure ATP specifically in neurons, however, we observed similar changes in human neuroblastoma cells (Supplemental Figure 3, A–E). These data indicate that TZ activates glycolysis in vivo. Together with measurements of brain TZ levels (Supplemental Figure 3F), they also indicate that TZ readily crosses the blood-brain barrier.

Although PGK1 produces ATP, oxidative phosphorylation is probably important for increasing ATP on the basis of the following: (a) pyruvate, the product of glycolysis and major substrate for the citric acid cycle, increased (Figure 1, F and G, and Supplemental Figure 2, A–C), and administration of TZ prevented the fall in pyruvate and ATP levels. Mitochondrial content (assessed by the ratio of mitochondrial DNA to nuclear DNA and by VDAC and PHB1 levels) also fell (Supplemental Figure 2, D–F). TZ partially prevented the decrease. As previously suggested (23), the increased pyruvate levels may have stimulated mitochondrial biogenesis. It would be difficult to measure ATP specifically in neurons, however, we observed similar changes in human neuroblastoma cells (Supplemental Figure 3, A–E). These data indicate that TZ activates glycolysis in vivo. Together with measurements of brain TZ levels (Supplemental Figure 3F), they also indicate that TZ readily crosses the blood-brain barrier.

**TZ decreases MPTP-induced neurodegeneration in mice.** MPTP can model aspects of dopamine neuron loss in mice (21). To determine whether PGK1 stimulation would slow or prevent MPTP-mediated deficits, we administered MPTP to the mice, followed...
by administration of TZ for the next 7 days, and an assay on day 7 (Figure 2A). Because individuals with PD present after the onset of neuron degeneration, we also asked whether delayed TZ administration would slow neuron loss and functional decline. Therefore, in some mice, we waited 7 days after delivering MPTP before starting the 7-day course of TZ treatment. We then performed an assay on day 14 (Figure 2A).

Over the course of 14 days, MPTP progressively decreased the levels of tyrosine hydroxylase (TH), the rate-limiting enzyme for generating dopamine. MPTP decreased TH levels in the SNc and striatum, reduced the numbers of TH-positive cells in the SNc, and decreased the intensity of TH immunostaining in the neuron projections into the striatum (Figure 2, B–G, and Supplemental Figure 2. TZ improves dopamine neuron and motor function in MPTP-treated mice. (A) Schematic for experiments in panels B–K. Eight-week-old C57BL/6 mice received 4 i.p. injections of MPTP (20 mg/kg at 2-hour intervals) or vehicle on day 0. Mice were then injected with TZ (10 μg/kg) or vehicle (0.9% saline) once a day for 1 week, and assays were performed on day 7. Other mice began receiving daily TZ or vehicle injections beginning on day 7, and assays were performed on day 14. n = 6. (B–D) Example of Western blots with TH and β-actin (protein loading control) in striatum and SNc on days 7 and 14 (B). Quantification of TH protein normalized to control (C and D). n = 6. (E) Example of immunostaining of TH in SNc and striatum. Scale bars: 100 μm (SNc) and 1 mm (striatum). Quantification of TH-positive neurons in SNc (F) and TH intensity in the striatum (G). n = 6. (H and I) Dopamine (DA) content in striatum and SNc. n = 6. (J) Percentage of TH-positive neurons that were positive for TUNEL staining. n = 6. (K) Behavioral response of mice in the rotarod test. Data reflect the duration that the mice remained on an accelerated rolling rod, normalized to mice on day 0. n = 8. Data represent examples and indicate the mean ± SEM. Blue indicates control and red indicates TZ treatment. *P < 0.05 and **P < 0.01, by Mann-Whitney U test for days 7 and 14. Supplemental Table 3 shows P values for all comparisons.

As a result, the dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) content of the striatum and SNc decreased (Figure 2, H and I, and Supplemental Figure 4, C–F). MPTP also increased the percentage of TH-positive cells that were TUNEL positive, indicating increased apoptosis (Figure 2J and Supplemental Figure 4, G and H). Beginning TZ treatment at the time we administered MPTP attenuated all these defects on day 7. When TZ delivery was delayed for 7 days after MPTP administration, it improved the abnormalities on day 14. Consistent with these biochemical defects, TZ prevented deficits in motor function on day 7, and it improved motor performance on day 14 after delayed administration (Figure 2K and Supplemental Figure 4, I and J).
These in vivo results in mice suggest that TZ slows or prevents MPTP-induced neurodegeneration, partially restores TH and dopamine levels, and improves motor function.

TZ enhancement of PGK1 activity slows neurodegeneration in 6-OHDA-treated rats. The compound 6-hydroxydopamine (6-OHDA) is delivered to rats to produce a model of dopamine neuron degeneration in PD (24). Previous studies have shown progressive cell death and injury between 2 and 12 weeks after administration of 6-OHDA (25–27). Therefore, we chose a 7-week course of observation. We injected 6-OHDA into the right striatum of rats, waited 2–5 weeks, and then initiated a 2-week course of TZ treatment (Figure 3A). In vehicle-treated rats, evidence of SNc cell apoptosis progressively increased from 2 to 7 weeks (Figure 3B and Supplemental Figure 5, A and B). However, irrespective of the delay before the start of treatment, we observed that TZ attenuated further cell loss. 6-OHDA also progressively decreased TH levels in the striatum and SNc (Figure 3C and Supplemental Figure 5, C–F). The percentage of TH-positive cells in the SNc and the intensity of TH immunostaining in the striatum also decreased (Figure 3, D and E). TZ partially reverted these abnormalities toward control values.

TZ enhancement of PGK1 activity slowed neurodegeneration in 6-OHDA–treated rats. The compound 6-hydroxydopamine (6-OHDA) is delivered to rats to produce a model of dopamine neuron degeneration in PD (24). Previous studies have shown progressive cell death and injury between 2 and 12 weeks after administration of 6-OHDA (25–27). Therefore, we chose a 7-week course of observation. We injected 6-OHDA into the right striatum of rats, waited 2–5 weeks, and then initiated a 2-week course of TZ treatment (Figure 3A). In vehicle-treated rats, evidence of SNc cell apoptosis progressively increased from 2 to 7 weeks (Figure 3B and Supplemental Figure 5, A and B). However, irrespective of the delay before the start of treatment, we observed that TZ attenuated further cell loss. 6-OHDA also progressively decreased TH levels in the striatum and SNc (Figure 3C and Supplemental Figure 5, C–F). The percentage of TH-positive cells in the SNc and the intensity of TH immunostaining in the striatum also decreased (Figure 3, D and E). TZ partially reverted these abnormalities toward control values.
is highly conserved in flies and mammals, and supplying TZ motor function as tested by climbing behavior (Figure 4C). PGK reduced brain ATP levels (Figure 4, A and B). It also disrupted Drosophila melanogaster with rotenone, a mitochondrial complex I inhibitor implicated in sporadic PD (29). Rotenone exposure reduced brain ATP levels (Figure 4, A and B). It also disrupted motor function as tested by climbing behavior (Figure 4C). PGK is highly conserved in flies and mammals, and supplying TZ neurons, TH intensity in the striatum, and dopamine content also continued to decrease further with time. Administration of TZ, even after the onset of neurodegeneration, slowed cell death, and it increased TH levels, dopamine content, and motor performance compared with vehicle-treated controls (Figures 2 and 3 and Supplemental Figures 4 and 5).

After MPTP and 6-OHDA administration, apoptotic cell death continued for 14 days and 7 weeks, respectively. Delayed TZ administration (beginning on day 7 in MPTP-treated mice and in week 5 in 6-OHDA-treated rats) slowed or prevented further apoptotic cell death. In MPTP-treated mice, dopamine levels, behavioral performance, and in some cases TH levels on day 7 continued to decrease further with time. Administration of TZ, together with rotenone minimized decrements in ATP content and motor performance.

Previous studies showed that TZ increases ATP by enhancing PGK1 activity (18, 30). We knocked down Pgtk in Drosophila by expressing RNAi and found that it abolished the protective effect of TZ on motor performance (Figure 4, D and E, vs. Figure 4C). Conversely, overexpression of PGK1 in Drosophila TH neurons, all neurons (Appl promoter), or all cells (actin promoter) made flies resistant to rotenone-induced behavioral defects (Figure 4F). In contrast, we found that expression in muscle was not protective. These results, together with earlier findings (18, 30), indicate that TZ protects TH neurons by activating PGK1.

TZ attenuates neurodegeneration in genetic models of PD. In addition to toxin-induced models, we tested fly, mouse, and human genetic models of PD. PINK1 mutations cause PD in humans; we therefore tested the human genetic models of PD. As an additional model of PD, we treated Drosophila melanogaster with rotenone, a mitochondrial complex I inhibitor implicated in sporadic PD (29). Rotenone exposure reduced brain ATP levels (Figure 4, A and B). It also disrupted motor function as tested by climbing behavior (Figure 4C). PGK is highly conserved in flies and mammals, and supplying TZ together with rotenone minimized decrements in ATP content and motor performance.

Figure 4. TZ enhances Pgtk activity to attenuate rotenone-impaired motor performance. (A) Schematic for experiments in panels B–F. Flies received rotenone (025 or 250 μM in food) with TZ (1 μM) or vehicle for 7 or 14 days. (B) Relative ATP content in the brains of w1118 flies that received 250 μM rotenone with or without TZ for 14 days. n = 6, with 200 fly heads for each treatment in each trial. (C) Climbing behavior of flies after 250 μM rotenone with TZ (1 μM) or vehicle for 7 days. Data show the percentage of flies that climbed up a tube (see Methods). n = 3, with 200 flies tested for each treatment in each trial. (D) Knockdown of Pgtk in offspring of actin-Gal4 crossed with UAS-Pgtk RNAi flies. Offspring of actin-Gal4 crossed with y; v1 F [CaryP] attP2 were used as a genetic background matched control. n = 3, with RNA collected from 30 fly heads for each sample. (E) Pgtk was knocked down in TH neurons by crossing UAS-Pgtk RNAi flies with flies carrying the TH neuron-specific promoter (TH-Gal4) to produce TH-Pgtk RNAi flies. Rotenone (250 μM) and TZ were administered as indicated for 7 days. Climbing behavior was measured on day 7. n = 8, with 200 flies tested for each treatment in each trial. (F) Pgtk (UAS-Pgtk) overexpression was driven by a dopaminergic neuron promoter (TH-Gal4), a pan-neuronal promoter (Appl-Gal4), a pan-cell promoter (Actin-Gal4), and a muscle-specific promoter (Mhc-Gal4). Rotenone (250 μM) was administered for 7 days, and climbing behavior was measured on day 7. n = 3, with 200 flies tested for each treatment in each trial. Data points represent individual groups of flies, and bars and whiskers show the mean ± SEM. Blue indicates controls and red indicates TZ treatment. Supplemental Table 3 shows statistical tests and P values for all comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001, by Kruskal-Wallis with a Dwass-Steele-Critchlow-Fligner test (E), 1-way ANOVA with Tukey’s test (C and E), paired t test (D), and unpaired t test (F).
Abnormal accumulation of α-synuclein, a major constituent of Lewy bodies, is a key feature of PD (36). Transgenic mice overexpressing WT human α-synuclein (mThy1-hSNCA) exhibit PD-like neurodegeneration at an advanced age (37). We began treating mThy1-hSNCA mice at 3 months of age with vehicle or TZ. When they were 15 months old, the vehicle-treated mice had substantial expression of human α-synuclein in the striatum and SNc (Figure 5, G–J) and impaired motor performance on the rotarod and pole tests (Figure 5K and Supplemental Figure 7). TZ treatment partially prevented these abnormalities.

We also tested the effect of TZ on dopamine neurons differentiated from induced pluripotent stem cells (iPSCs). LRRK2 G2019S is the most common LRRK2 mutation and is associated with approximately 4% of familial PD cases and approximately 1% of sporadic PD cases (38). Dopamine neurons derived from LRRK2G2019S iPSCs recapitulate PD features including abnormal α-synuclein accumulation (39). We studied such neurons generated from 2 patients. After 30 days of differentiation, the dopamine neurons showed no overt signs of neurodegeneration (Supplemental Figure 8). However, approximately 60% of the LRRK2 G2019S dopamine neurons had accumulated α-synuclein compared with approximately 15% of dopamine neurons from healthy individuals (Figure 6, A and B). Addition of TZ for 24 hours increased the ATP content and reduced the percentage of LRRK2 G2019S dopamine neurons with elevated α-synuclein accumulation (Figure 6, A–C).

In the Parkinson’s Progression Markers Initiative database, individuals with PD who were taking TZ had a reduced rate of progressive motor disability. In the past, assessment of whether an agent might affect PD has been largely limited to animal models. Three factors allowed us to assess efficacy in humans. First, TZ is a relatively commonly used drug. Second, availability of human clinical databases allowed us to test for a TZ effect. Third, tamsulosin can serve as a control for TZ. Like TZ, tamsulosin is an α1-adrenergic antagonist, and, like TZ, tamsulosin is prescribed for benign pros-
tastic hyperplasia. However, in contrast to TZ, tamsulosin does not have a quinazoline motif that binds to and enhances PGK1 activity.

PD is common in older men, its incidence increases markedly after age 60, and the prevalence of the disease in men is approximately 1.5 times that in women (40). TZ is prescribed for benign prostatic hyperplasia, a disease that also affects older men. Therefore, we suspected that some patients with PD used TZ, and we hypothesized that they would have a reduced rate of disease progression. To test this hypothesis, we interrogated the Parkinson’s Progression Markers Initiative (PPMI) database. This database enrolls patients with PD shortly after diagnosis and follows their motor function as determined by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Part 3 (41). Although this clinical database is small, it is relatively unique in assessing motor progression. We identified 15,409 individuals with PD who used TZ/DZ/AZ (4821 per-person years) (Table 2). For a comparison group, we chose patients with PD who were taking tamsulosin, which controlled for use of an α1-adrenergic antagonist and for the presence of benign prostatic hyperplasia. We identified 15,409 individuals with PD who were taking tamsulosin (21,409 person years). To obtain a list of diagnostic codes associated with PD, we first identified the 497 most common diagnostic codes in the group of individuals with PD. Then, 2 neurologists who care for patients with PD identified 79 potentially PD-related diagnoses (Supplemental Table 1).

Using a quasi-Poisson generalized linear model, we found that the relative risk (RR) of having any of the 79 PD-related diagnostic codes was 0.78 (95% CI: 0.74–0.82) for the TZ/DZ/AZ group relative to the individuals on tamsulosin (P < 0.00001). Of the 79 PD-related codes, we found a reduced risk in 69 codes among patients with PD who were taking TZ/DZ/AZ versus those taking tamsulosin (Figure 8A). Moreover, 41 diagnostic codes were statistically significantly decreased in the PD patients taking TZ/DZ/AZ (Table 1). The progression of motor disability was slowed in those patients (Figure 7, Supplemental Figure 10, and Table 1). In contrast to TZ, DZ, and AZ, tamsulosin lacks a quinazoline motif for binding to PGK1. Consistent with that, tamsulosin did not rescue tyrosine hydroxylase levels in MPTP-treated mice (Supplemental Figure 9, A and B). We identified 13 men in the PPMI database who were using TZ, DZ, or AZ (TZ/DZ/AZ) (Table 1). The progression of motor disability was slowed in those patients (Figure 7, Supplemental Figure 10, and Table 1).

PD is common in older men, its incidence increases markedly after age 60, and the prevalence of the disease in men is approximately 1.5 times that in women (40). TZ is prescribed for benign prostatic hyperplasia, a disease that also affects older men. Therefore, we suspected that some patients with PD used TZ, and we hypothesized that they would have a reduced rate of disease progression. To test this hypothesis, we interrogated the Parkinson’s Progression Markers Initiative (PPMI) database. This database enrolls patients with PD shortly after diagnosis and follows their motor function as determined by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale Part 3 (41). Although this clinical database is small, it is relatively unique in assessing motor progression. We identified 15,409 individuals with PD who used TZ/DZ/AZ (4821 per-person years) (Table 2). For a comparison group, we chose patients with PD who were taking tamsulosin, which controlled for use of an α1-adrenergic antagonist and for the presence of benign prostatic hyperplasia. We identified 15,409 individuals with PD who were taking tamsulosin (21,409 person years). To obtain a list of diagnostic codes associated with PD, we first identified the 497 most common diagnostic codes in the group of individuals with PD. Then, 2 neurologists who care for patients with PD identified 79 potentially PD-related diagnoses (Supplemental Table 1).

Using a quasi-Poisson generalized linear model, we found that the relative risk (RR) of having any of the 79 PD-related diagnostic codes was 0.78 (95% CI: 0.74–0.82) for the TZ/DZ/AZ group relative to the individuals on tamsulosin (P < 0.00001). Of the 79 PD-related codes, we found a reduced risk in 69 codes among patients with PD who were taking TZ/DZ/AZ versus those taking tamsulosin (Figure 8A). Moreover, 41 diagnostic codes were statistically significantly decreased in the PD patients taking TZ/DZ/AZ.

The crystal structure of TZ with PGK1 (18) suggested that related drugs with quinazoline motifs might also enhance PGK1 activity. Consistent with that possibility, doxazosin (DZ) and alfuzosin (AZ) increased glycolysis in M17 cells and tyrosine hydroxylase levels in MPTP-treated mice (Supplemental Figure 9, A and B). We identified 13 men in the PPMI database who were using TZ, DZ, or AZ (TZ/DZ/AZ) (Table 1). The progression of motor disability was slowed in those patients (Figure 7, Supplemental Figure 10, and Table 1).
AZ versus those on tamsulosin, whereas only 2 diagnostic codes were significantly increased in the TZ/DZ/AZ group.

To estimate PD-related benefits and risks attributable to TZ/DZ/AZ versus tamsulosin, we calculated the RR for clinically relevant groupings of the 79 PD-related codes. Relative to patients with PD taking tamsulosin, those on TZ/DZ/AZ had reduced clinic and hospital visits for motor symptoms (RR 0.77; 95% CI: 0.70–0.84), nonmotor symptoms (RR 0.78; 95% CI: 0.73–0.83), and PD complications (RR 0.76; 95% CI: 0.71–0.82) (Figure 8B, Supplemental Table 1, and Supplemental Table 2). Of note, dopamine analogs do not treat PD symptoms such as dementia and neuropsychiatric manifestations (3). However, the RR for these diagnostic codes was also less than 1.0.

These data suggest that under real-world conditions, TZ and related drugs that enhance PGK1 activity reduce PD signs, symptoms, and complications.

**Individuals who used TZ/DZ/AZ had a decreased risk of PD diagnosis.** We also used the Truven database to test whether TZ/DZ/AZ might reduce the frequency of PD diagnoses. We identified 78,444 PD-free enrollees who were taking TZ/DZ/AZ. During a follow-up duration of 284 ± 382 days (mean ± SD), a total of 118 individuals (0.15%) developed PD. In contrast, in an equal-sized cohort of PD-free enrollees taking tamsulosin and matched for age and follow-up duration (284 ± 381 days), 190 individuals (0.25%) developed PD. The HR from the Cox proportional hazards regression for the matched cohort was 0.62 (95% CI: 0.49–0.78; \( P < 0.0001 \)).

**Discussion**

Our results indicate that in both toxin-induced and genetic models of PD in multiple animal species, enhancement of PGK1 activity slows or prevents neurodegeneration in vivo, thereby increasing dopamine levels and improving motor performance. Enhancement of PGK1 activity showed beneficial effects, even when begun after the onset of neurodegeneration. Moreover, interrogation of 2 independent databases suggested that TZ and related quinazoline agents slowed disease progression, reduced PD-related complications in individuals with PD, and reduced the risk of receiving a PD diagnosis.

Evidence from our present and earlier experiments indicates that TZ elicits its beneficial effects in PD by enhancing the activity of PGK1 and not by inhibiting the \( \alpha_1 \)-adrenergic receptor. Our earlier experiments and crystal structure showed that the quinazoline motif of TZ binds PGK1 near the nucleotide binding site (18). Studies with recombinant PGK1, studies using cultured cells, and measurements in brain following in vivo delivery all revealed a biphasic relationship between the concentration of TZ and ATP levels (18). In the present study, tamsulosin inhibited \( \alpha_1 \)-adrenergic receptors, but its structure lacks a quinazoline group that binds PGK1, and it did not enhance glycolysis or prevent the reduction of tyrosine hydroxylase levels in MPTP-treated mice. In contrast, 2 drugs that have a structure similar to that of TZ (DZ and AZ) enhanced glycolysis in vitro and protected MPTP-treated mice.
Knockdown of *Pgk1* in *Drosophila* TH neurons abolished the protective effect of TZ. Overexpression of PGK1 in flies, mice, and fish phenocopied the effects of TZ (18, 30). TZ was active in *Drosophila melanogaster*, which do not have α1-adrenergic receptors. Allosteric and covalent regulatory mechanisms have been identified for most glycolytic enzymes. For example, insulin-stimulated deacetylation increases PGK1 activity, and disrupting that regulation results in glycolytic insufficiency (42).

Previous work has identified numerous genetic mutations and several environmental factors that cause or predispose individuals to PD (11–16, 43). As indicated above, reduced energy metabolism and decreased ATP levels are a feature of many of these environmental and genetic factors, as is aging, the major PD risk factor. Therefore, enhancing glycolysis might slow progression in PD of several etiologies.

This study does not reveal how enhanced glycolysis slows neurodegeneration and progression in PD. However, the increased ATP levels produced by TZ may be key. ATP has properties of a hydrotrope; it can prevent aggregate formation and dissolve previously formed protein aggregates (44, 45). Moreover, the transition between aggregate stability and dissolution occurs in a narrow range at physiological ATP concentrations. We speculate that by elevating ATP levels, TZ facilitates the solubilization of aggregates, including α-synuclein, and prevents the neurodegeneration of PD. However, other mechanisms are also possible including ATP-dependent disaggregases and chaperones (such as hsp90) that reduce apoptosis (18, 44, 45).

Table 2. Subjects from the Truven MarketScan database

<table>
<thead>
<tr>
<th></th>
<th>Tamsulosin</th>
<th>TZ</th>
<th>DZ</th>
<th>AZ</th>
<th>TZ/DZ/AZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of enrollees</td>
<td>15,409</td>
<td>1173</td>
<td>1177</td>
<td>529</td>
<td>2879</td>
</tr>
<tr>
<td>Person-years of exposure</td>
<td>21,409</td>
<td>2046</td>
<td>1967</td>
<td>808</td>
<td>4821</td>
</tr>
<tr>
<td>Dosage mg/d, mean ± SD</td>
<td>0.4 ± 0.0</td>
<td>4.6 ± 3.1</td>
<td>3.9 ± 2.3</td>
<td>10</td>
<td>NA</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>77.2 ± 7.7</td>
<td>77.8 ± 7.4</td>
<td>77.6 ± 7.7</td>
<td>75.9 ± 8.0</td>
<td>77.4 ± 7.7</td>
</tr>
</tbody>
</table>

Summary of the number of enrollees, duration of exposure, and dose of drugs. Age refers to the age of the patient at the first observed medication-dispensing event. The first event can be the age of a patient at the time of a refill of a prescription that was begun prior to entry of the patient into the Truven database, or it can be the age at which the patient started the medication during the Truven observation period.

This study also has limitations, including those for toxin-induced and genetic models of PD (46). Toxins such as MPTP and rotenone can cause PD in humans and PD-like disease in animals. Genetic defects also cause PD in humans and PD-like disease in animals. However, most PD is age related, with etiologies that remain unidentified and are likely complex. Moreover, no current model unequivocally or accurately predicts therapeutic benefit or pathogenesis. It is precisely for these reasons that we used multiple animal models of PD and that we sought out human data. A second limitation is that our analysis of human databases was limited to men, because they are treated for benign prostatic hyperplasia. However, we expect that similar results would be obtained in women. Third, our data from humans are retrospective; however, these data provide compelling evidence that cannot be obtained from animal models alone. Fourth, our analysis of the PPMI and Truven databases compared patients on TZ/DZ/AZ with those on tamsulosin. Although all the drugs were prescribed for benign prostatic hyperplasia, we cannot exclude the possibility that some other factor might have influenced prescribing behavior. For example, orthostatic hypotension is a complication of both the autonomic dysfunction in PD and of the drugs, and there are reports suggesting that tamsulosin may elicit less orthostatic hypotension than TZ (47). However, such an effect would not explain the PPMI conclusions. Interestingly, the risk of orthostatic hypotension and falls was reduced, not increased, for patients with PD taking TZ/DZ/AZ versus those on...
tamsulosin. In PD, neurons that have not yet degenerated almost certainly have compromised cellular function (28), and we speculate that TZ/DZ/AZ improved their functional integrity.

Results from this study, together with earlier data, led us to additional speculations. First, TZ is already used clinically, and in this regard, it is interesting that several studies reported that TZ improved glucose metabolism in patients with diabetes (48, 49). That observation has gone unexplained. We speculate that stimulation of PGK1 activity might have been responsible. Consistent with that conjecture and with the conclusion that an α1-adrenergic receptor antagonistic effect was not responsible, we found that α1-adrenergic receptor antagonists structurally unrelated to TZ lacked that effect. In addition, disruption of the α1a-adrenergic receptor in mice had an effect opposite of that induced by TZ (50). Second, loss-of-function PGK1 mutations cause recessive hemolytic anemia, myopathy, seizures, and intellectual disability. However, other studies have reported Parkinsonism (51, 52), and the authors speculated that reduced ATP generation in the SNc may have been responsible. Third, PD occurs approximately 1.5 times more frequently in men than in women (53). Why males are more predisposed to PD is unknown. However, it may be worth noting that the PGK1 gene is located on the X chromosome. Thus, the consequences of DNA sequence variations that could subtly reduce PGK1 levels or activity might more often manifest in men than in women.

Our findings that TZ increased glycolysis and prevented progressive neurodegeneration suggest that energy deficits might either be a pathogenic factor in the pathogenesis of PD or predispose individuals to PD in the presence of environmental or genetic etiologies (11, 16). These findings identify a protein and a pathway that might be targeted to slow or prevent neurodegeneration in PD and potentially other neurodegenerative diseases with altered energy balance (54).

Methods
The Supplemental Methods contain information on the materials, reagents, experimental procedures, and analysis methods used in this study.

Statistics. For experiments to quantify animal behavior and for sample collections, the experimenters were blinded to the genotype and intervention, and the studies were conducted by 2 different experimenters. The number of animals studied was based on our past experience and preliminary data. In all figures, data points are from individual mice and rats or groups of flies. We did not exclude any data points from this study. Data in the figures indicate the mean ± SEM. Blue indicates controls, and red indicates TZ treatment. Statistical significance for comparisons between data sets was primarily done with nonparametric tests. For studies of fly motor performance, our previous studies showed that within a group of flies (15–50 flies for 1 data point), the data fit a Gaussian distribution. Moreover, data for multiple groups of flies also fit a Gaussian distribution. Therefore, parametric tests were used to evaluate statistical significance in studies using flies, and ANOVA evaluations were 1 way. All statistical tests were 2 tailed. A P value of less than 0.05 was considered statistically significant. Supplemental Table 3 shows the statistical tests used for all data and the resulting P values for comparisons.

Study approval. All experiments using mice and rats were approved by the IACUC of Peking University in Beijing (approval nos. LSC-Liul-1 and LSC-Liul-2).

Author contributions
RC designed and performed many of the experiments and analyzed the data. YZ and YL performed fly and mouse studies. IFC and AC performed LRRK2 iPSC studies. AR designed the LRRK2-mutant iPSC studies. JES and PMP performed the analysis of the Truven database. YY, ZC, and WS performed parts of the animal behavior tests. JLS and NSN performed the PPMI database analysis. YH, CZ, and LG provided technical support and data analysis. XJ designed experiments. MJW designed experiments and analyzed data. LL designed and supervised experiments and analyzed data. RC, AR, MJW, and LL wrote the manuscript.

Acknowledgments
The authors thank Carles Calatayud (Center of Regenerative Medicine in Barcelona, Hospital Duran i Reynals, Hospital de Llobregat, Barcelona, Spain) for help and advice with iPSC cultures. We thank Andrew Thurman (Department of Internal Medicine, Carver College of Medicine, University of Iowa) for assistance with the statistical analysis. This work was supported by the National Natural Science Foundation of China (NSFC) (91649201 and 31771121, to LL) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYX201706, to LL); the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-69706-R, to AR, and BFU2016-80870-P, to AC); and the Instituto de Salud Carlos III – ISCIII/FEDER (Red de Terapia Celular: TerCel RD16/0011/0024 and PIE14/00061, to AR). Additional support was provided by the European Research Council (ERC) 2012-StG (311736- PD-HUMODEL, to AC); the AGAUR (Agency for Management of University and Research Grants (2017-SGR-899); the CERCA Programme/Generalitat de Catalunya (to AR); and the Roy J. Carver Charitable Trust and the Pappajohn Biomedical Institute (to MJW). MJW is an investigator at the Howard Hughes Medical Institute.

Address correspondence to: Michael J. Welsh, 169 Newton Road, 6332 PBDB, Iowa City, Iowa 52242, USA. Phone: 319.335.7619; Email: michael-welsh@uiowa.edu. Or to: Lei Liu, Beijing Institute for Brain Disorders and Beijing Tiantan Hospital, Capital Medical University, Youanmen, Beijing 100069, China. Phone: 010.8395.0371; Email: leiliu@ccmu.edu.cn.

6. Breah H, Del Tredici K. Neuropathological stag-


